论文部分内容阅读
目的评价唑来膦酸联合化疗治疗晚期非小细胞肺癌骨转移的临床疗效及不良反应。方法回顾性分析使用唑来膦酸联合化疗治疗晚期非小细胞肺癌骨转移48例,唑来膦酸4 mg,每3周1次,化疗每3周为一周期。对治疗前、治疗后1周和6周的有效指标———疼痛评分(NRS)、缓解率、止痛药使用剂量、行为状态评分(KPS)、骨转移灶效果、血清钙浓度、碱性磷酸酶(AKP)进行比较,并分析不良反应事件。结果治疗1周后疼痛缓解率为75.61%6,周后为82.93%。治疗后1、6周NRS较治疗前显著下降(P<0.05),KPS则较治疗前显著升高(P<0.05)。治疗后6周血清钙和AKP较治疗前显著下降(P<0.05)。治疗期间出现Ⅰ度或Ⅱ度血液学毒性,2例患者出现新转移灶,无骨相关事件发生。结论唑来膦酸对骨转移引起的疼痛有良好的止痛效果,迅速降低血钙,具有良好的耐受性,给药方便,能提高患者生活质量。
Objective To evaluate the clinical efficacy and adverse reactions of zoledronic acid combined with chemotherapy in the treatment of advanced non-small cell lung cancer with bone metastases. Methods 48 cases of bone metastasis of advanced non-small cell lung cancer treated with zoledronic acid combined with chemotherapy were retrospectively analyzed. Zoledronic acid was given 4 mg once every 3 weeks and once every 3 weeks of chemotherapy. The effective indexes of pre-treatment, post-treatment 1 week and 6 weeks were: pain score (NRS), remission rate, pain medication dosage, behavioral status score (KPS), bone metastases effect, serum calcium concentration, Enzymes (AKP) were compared and adverse events were analyzed. Results After 1 week of treatment, the pain relief rate was 75.61% 6 and 82.93% after the week. NRS at 1 week and 6 weeks after treatment significantly decreased (P <0.05), and KPS increased significantly (P <0.05) before treatment. Serum calcium and AKP decreased significantly 6 weeks after treatment (P <0.05). I or II degree hematologic toxicity was observed during treatment, and two new metastases occurred and no bone-related events occurred. Conclusion Zoledronic acid has a good analgesic effect on pain caused by bone metastasis, rapidly lowering blood calcium, has good tolerability, convenient administration, and improves quality of life of patients.